Piper Sandler Reiterates Overweight on Amgen, Raises Price Target to $542

Benzinga · 2d ago
Piper Sandler analyst David Amsellem reiterates Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $457 to $542.